NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
Amgen
I-Mab Biopharma US Limited
Merck Sharp & Dohme LLC
Royal Marsden NHS Foundation Trust
Incyte Corporation
Merck Sharp & Dohme LLC
Xencor, Inc.
Incyte Corporation
Genentech, Inc.
Novartis
TransThera Sciences (Nanjing), Inc.
Esperas Pharma Inc.
Exelixis
Stanford University
Compugen Ltd
Cyteir Therapeutics, Inc.
BeiGene
Sellas Life Sciences Group
Vincerx Pharma, Inc.
Vincerx Pharma, Inc.
Mundipharma Research Limited
Hutchmed
Cantargia AB
Xencor, Inc.
Amgen
TransThera Sciences (Nanjing), Inc.
Eli Lilly and Company
MacroGenics
Corvus Pharmaceuticals, Inc.
Tempest Therapeutics
Xencor, Inc.
Nektar Therapeutics
Novartis
Corcept Therapeutics
Xencor, Inc.
Incyte Corporation
Hoffmann-La Roche
Bayer
AbbVie
AbbVie
Novartis
Incyte Corporation
Incyte Corporation
Gilead Sciences
Novartis
Bristol-Myers Squibb
AstraZeneca
Novartis
Novartis